Nuvalent’s Noci sells $321k in shares

Published 01/08/2025, 21:42
Nuvalent’s Noci sells $321k in shares

Nuvalent , Inc. (NASDAQ:NUVL), a $5.6 billion market cap biotech company, saw Chief Development Officer Darlene Noci sell 4,000 shares of Class A Common Stock on July 30, 2025, for a total of $321,440. The sales were executed at a weighted average price of $80.36, with individual prices ranging from $79.98 to $80.92. According to InvestingPro data, analysts maintain price targets between $100-$140, suggesting potential upside from current levels.

On the same day, Noci also exercised options to acquire 4,000 shares of Class A Common Stock at a price of $27.85, totaling $111,400.

These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. Following these transactions, Noci directly owns 48,034 shares of Nuvalent, Inc.

In other recent news, Nuvalent, Inc. has commenced its Phase 3 ALKAZAR clinical trial, evaluating neladalkib for advanced ALK-positive non-small cell lung cancer. This trial will compare neladalkib to alectinib, a current standard of care, and has already dosed its first patient. The study aims to enroll approximately 450 patients. Additionally, Nuvalent is planning a rolling New Drug Application submission for its ROS1-selective inhibitor, zidesamtinib, in July 2025, with the process expected to complete by the third quarter of that year. This follows positive pivotal data in previously treated ROS1-positive NSCLC patients. In terms of analyst coverage, Goldman Sachs initiated coverage on Nuvalent with a Buy rating and a price target of $105, citing the efficacy and safety profile of zidesamtinib. UBS also raised its price target for Nuvalent to $114, maintaining a Buy rating, after the release of pivotal Phase 2 data for zidesamtinib. These developments reflect growing interest in Nuvalent’s pipeline and its potential impact on lung cancer treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.